What is the difference between Larazotide and Teduglutide?

Larazotide: Synthetic octapeptide that prevents zonulin-mediated tight junction opening; maintains intestinal epithelial barrier integrity Teduglutide: GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility

Is Larazotide FDA approved?

Larazotide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Teduglutide FDA approved?

Teduglutide is FDA approved (FDA status current as of 2012-12-21). This regulatory status is provided for research and educational context only.

How is Larazotide administered in research settings?

In research settings, Larazotide is typically administered via the oral route. PeptideBase does not provide dosing or administration instructions.

How is Teduglutide administered in research settings?

In research settings, Teduglutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Larazotide vs Teduglutide

Peptide Comparison

Larazotide vs Teduglutide

Both are Tissue Repair peptides.

Larazotide

AT1001

RecoveryInvestigationalResearch Only

Half-life: ~30 minutes (local gut action)

11 providers listed

Full Larazotide profile →

Teduglutide

Gattex

RecoveryFDA ApprovedPrescription

Half-life: ~2 hours

No providers listed yet

Full Teduglutide profile →

Bottom line

Teduglutide is FDA-approved, while Larazotide is investigational — the clearest structural difference between them.

Quick Verdict

Larazotide

Evidence

Clinical

Half-life

~30 minutes (local gut action)

Teduglutide

Evidence

Clinical

Half-life

~2 hours

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Teduglutide
Further along in FDA review	Teduglutide
Less frequent dosing (longer half-life)	Teduglutide
Oral administration option	Larazotide
More provider options (11 vs 0)	Larazotide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Larazotide

Teduglutide

Mechanism Family

Tissue Repair

Half-life

~30 minutes (local gut action)

~2 hours

FDA Status

investigational

approved

Admin Routes

oral

subcutaneous

Availability

Research Only

Prescription

Providers

11 listed

None listed

FDA Update

—

Dec 2012

Avail. Notes

Tight junction regulator (AT-1001) for celiac disease. Phase 3 ILIT-1 (NCT02633956) failed primary endpoint 2019. No NDA filed. Additional Phase 3 planned by ImmunoGenX. Investigational.

FDA-approved GLP-2 analog. Brand: Gattex (NDA 203441, Dec 2012). Indicated for short bowel syndrome in adults and paediatric patients. Daily subcutaneous injection. Prescription only.

Research Evidence

Larazotide

ClinicalRCT · 3 key studies · most recent 2026

Teduglutide

ClinicalRCT · 9 key studies · most recent 2026

Research Citations

Larazotide

RCT2015 · Gastroenterology

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized control…

Cohort2026 · Digestion

Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stre…

RCT2012 · American Journal of Gastroenterology

A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during glu…

Teduglutide

Cohort2026 · Clin Nutr

From childhood to adulthood in chronic intestinal failure: A nationwide study.

Cohort2026 · Bioconjug Chem

A Long-Acting Glucagon-like Peptide 2 Protracted by Coomassie Brilliant Blue to Enhance Intestinal Growth in…

Cohort2026 · JPGN Rep

PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.

Review2026 · Curr Opin Gastroenterol

Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?

+5 more

About Larazotide

Synthetic octapeptide that prevents zonulin-mediated tight junction opening; maintains intestinal epithelial barrier integrity

Research Areas

tight junction restorationintestinal barrier repairleaky gut prevention

About Teduglutide

GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility

Research Areas

intestinal growthgut repairabsorptive surface restorationshort bowel syndrome treatment

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Larazotide

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Teduglutide

Reported (Unverified — Pending Clinical Review)

GI malignancy or historycolorectal polyps (monitor)

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Larazotide

11 listed

Browse directory →

Providers offering

Teduglutide

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Tissue Repair Comparisons

Browse all peptides →

Educational research tools — not medical advice.